This significant effect was derived by the use of fibrates ( RR 0.80 , 95 % CI 0.73–0.87 , P < 0.001 , I2 = 22 % ) and meta-regression analysis showed that this benefit was consistent with an absolute reduction in low-density lipoprotein cholesterol .
Meta-regression analyses failed to demonstrate a significant association of pharmacologically increased high-density lipoprotein cholesterol with key endpoints .
Conclusion The use of high-density lipoprotein cholesterol modifying treatments had no significant effect on cardiovascular mortality , stroke or all-cause mortality .
The beneficial effect on myocardial infa rct ion was lost when drugs were used with statin therapy
Background The effects of increasing high-density lipoprotein cholesterol on cardiovascular outcomes remain uncertain .
Design We conducted a meta- analysis to investigate the effects of high-density lipoprotein cholesterol modifiers ( niacin , fibrates and cholesteryl ester transfer protein inhibitors ) on cardiovascular outcomes .
The Treatment of Cerebrovascular Disease With Clofibrate: Final Report of the Veterans Administration Cooperative Study of Atherosclerosis, Neurology Section
A cooperative study in 20 Veterans Administration hospitals investigated the effect of clofibrate on morbidity and mortality due to atherosclerotic vascular disease in men with either an established cerebral infa rct ion or transient cerebrovascular ischemic attacks ( TIA ) . Follow-up observations were made for up to 4.5 years in 532 patients assigned on a r and om basis to placebo medication or to treatment with 2 gm of clofibrate daily . Baseline and follow-up cholesterol and triglyceride levels were measured . Recurrence of cerebral infa rct ion was increased in patients receiving clofibrate as compared to controls . The incidence of new myocardial infa rct ion and new TIA was similar in both groups . Despite the more frequent strokes in treated patients , they had a decrease in mortality , partially explained by a lower death rate from these recurrences . There was no correlation between pretreatment lipid ( cholesterol and triglyceride ) values and the result of therapy . Use of clofibrate , however , was associated with a slight reduction of cholesterol and a sustained fall in triglyceride . These findings do not support recently published reports that clofibrate reduces the occurrence of myocardial ischemia ; however , the investigative design and type of data collected in these various studies are different and make it difficult to compare results
This significant effect was derived by the use of fibrates ( RR 0.80 , 95 % CI 0.73–0.87 , P < 0.001 , I2 = 22 % ) and meta-regression analysis showed that this benefit was consistent with an absolute reduction in low-density lipoprotein cholesterol .
Meta-regression analyses failed to demonstrate a significant association of pharmacologically increased high-density lipoprotein cholesterol with key endpoints .
Conclusion The use of high-density lipoprotein cholesterol modifying treatments had no significant effect on cardiovascular mortality , stroke or all-cause mortality .
The beneficial effect on myocardial infa rct ion was lost when drugs were used with statin therapy
Background The effects of increasing high-density lipoprotein cholesterol on cardiovascular outcomes remain uncertain .
Design We conducted a meta- analysis to investigate the effects of high-density lipoprotein cholesterol modifiers ( niacin , fibrates and cholesteryl ester transfer protein inhibitors ) on cardiovascular outcomes .